ReviewJACC. Advances2022
The Utilization and Interpretation of Cardiac Biomarkers During Pregnancy:
Review in JACC. Advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Cardiac Biomarkers and Pregnancy-Associated Cardiovascular Disease.Current cardiology reports · 2026Review
- Bridging the Gap Between Genetic Cardiomyopathies and Pregnancy.JACC. Advances · 2026Article
- Cardiac biomarkers in women with high-risk pregnancies: short-term outcomes from the Heidelberg Cardio-Obstetrics Registry.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Review
- Role of biomarkers in identifying women at risk of hypertension and renal dysfunction on follow-up after severe preeclampsia.Journal of human hypertension · 2025Article
- Delayed recognition of peripartum cardiomyopathy presenting with severe heart failure: a case report.European heart journal. Case reports · 2025Article
- Cardiovascular-obstetric state-of-the-art review: pulmonary hypertension in pregnancy.Singapore medical journal · 2025Review
- Maternal heart failure: state-of-the-art review.Heart failure reviews · 2025Review
- Cardio-Obstetrics Team-Based Management of a Pregnant Patient With Severe Bioprosthetic Aortic Valve Disease.JACC. Case reports · 2024Article
- Biomarkers in Peripartum Cardiomyopathy-What We Know and What Is Still to Be Found.Biomolecules · 2024Review
- High-Sensitivity Troponin T and I Among Pregnant Women in the US-The National Health and Nutrition Examination Survey, 1999-2004.JAMA cardiology · 2023Article
- Dynamics of NT-proBNP in Pregnancy: Why Values May Be Elevated in the First Trimester.JACC. Advances · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac biomarkers are widely used in the nonpregnant population when acute cardiovascular (CV) pathology is suspected; however, the behavior of these biomarkers in the context of pregnancy is less well understood. Pregnant individuals often have symptoms that mimic those of cardiac dysfunction, and complications of pregnancy may include CV disease. This paper will summarize our current knowledge on the use of cardiac biomarkers in pregnancy and provide suggestions on how to use these tools in clinical practice based on the available evidence. Natriuretic peptides and troponin should not be measured routinely in uncomplicated pregnancy, where values should remain low as in the nonpregnant population. In the context of pre-existing or suspected CV disease, these biomarkers retain their negative predictive value. Elevations of both natriuretic peptides and troponin may occur without clear clinical significance in the immediate postpartum period. Elevations of these markers should always prompt further investigation into possible CV pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.